BeiGene

BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.

memo

A summary of the latest developments from 12 studies in the treatment of non-small cell lung cancer (NSCLC), gastric cancers and other solid tumors presented at ESMO 2022.

Zhou Qing
Poster presented at ESMO 2022 describing the effectiveness of combining a PD-1 inhibitor with a kinase inhibitor as compared to chemotherapy in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-PD-[L]1 antibody.

Chat with BeiGene

Close